Entacapone. A review of its use in Parkinson's disease (Q33706744)

28 July 2017

1 reference

title

Entacapone. A review of its use in Parkinson's disease (English)

1 reference

28 July 2017

1 reference

K J Holm

1

1 reference

28 July 2017

C M Spencer

series ordinal

2

1 reference

28 July 2017

publication date

1 July 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

58

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

159-177

1 reference

The natural history of Parkinson's disease

28 July 2017

cites work

1 reference

12 December 2020

Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone

1 reference

12 December 2020

Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone

1 reference

12 December 2020

Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis

1 reference

12 December 2020

Issues in the early diagnosis of Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease

1 reference

12 December 2020

Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers

1 reference

12 December 2020

Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets

1 reference

12 December 2020

Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production

1 reference

12 December 2020

Management of motor fluctuations in Parkinson's disease

1 reference

12 December 2020

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

1 reference

12 December 2020

Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.

1 reference

12 December 2020

A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease

1 reference

12 December 2020

The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers

1 reference

12 December 2020

Extending levodopa action: COMT inhibition

1 reference

12 December 2020

Catechol- O -methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone

1 reference

12 December 2020

New Pharmacotherapy for Parkinson's Disease

1 reference

12 December 2020

Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans

1 reference

12 December 2020

Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson's disease: review and current status

1 reference

12 December 2020

Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction

1 reference

12 December 2020

The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease

1 reference

12 December 2020

Simultaneous MAO‐B and COMT inhibition in L‐dopa‐treated patients with parkinson's disease

1 reference

12 December 2020

Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients

1 reference

12 December 2020

Levodopa therapy: consequences of the nonphysiologic replacement of dopamine

1 reference

12 December 2020

Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease

1 reference

12 December 2020

[11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold

1 reference

12 December 2020

1 reference

12 December 2020

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

1 reference

12 December 2020

The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise

1 reference

12 December 2020

General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase

1 reference

12 December 2020

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

12 December 2020

COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise

1 reference

12 December 2020

Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition

1 reference

12 December 2020

Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease.

1 reference

12 December 2020

Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease

1 reference

12 December 2020

Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers

1 reference

12 December 2020

Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease

1 reference

12 December 2020

The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine*

1 reference

12 December 2020

Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions

1 reference

12 December 2020

COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers

1 reference

12 December 2020

10.2165/00003495-199958010-00017

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1051269477

0 references

1 reference